Cancer stem cells at the crossroads of current cancer therapy failures-Radiation oncology perspective

Seminars in Cancer Biology

Volumn 20, Issue 2, 2010, Pages 116-124

  Koch, Ulrike ^a   Krause, Mechthild ^a   Baumann, Michael ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

Biomarker; Cancer stem cells; Local tumour control; Molecular targeting; Radiotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; CD133 ANTIGEN; HERMES ANTIGEN; NESTIN;

CANCER CONTROL; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STEM CELL; CELL ACTIVITY; CELL HYPOXIA; CYTOLOGY; HUMAN; NONHUMAN; PROGNOSIS; RADIATION DOSE; RADIATION EXPOSURE; RADIOSENSITIVITY; REVIEW; RHABDOID TUMOR; TERATOMA; TREATMENT FAILURE; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; ANIMAL; NEOPLASMS; PATHOLOGY;

ANIMALS; HUMANS; NEOPLASMS; NEOPLASTIC STEM CELLS; TREATMENT FAILURE;

EID: 77953810074     PISSN: 1044579X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semcancer.2010.02.003     Document Type: Review

References (169)

1. DeVita V.T., Hellmann S., Rosenberg S.A. Cancer-principles & practice of oncology 2008, Lippincott Williams & Wilkins, a Wolters Kluwer buisness, Philadelphia. eighth ed.
2. DeVita V.T., Chu E. A history of cancer chemotherapy. Cancer Res 2008, 68(21):8643-8653.
3. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Thun M.J. Cancer statistics, 2009. CA Cancer J Clin 2009, 59(4):225-249.
4. La Vecchia C., Bosetti C., Lucchini F., Bertuccio P., Negri E., Boyle P., et al. Cancer mortality in Europe, 2000-2004, and an overview of trends since. Ann Oncol 1975, 2009.
5. Connell P.P., Hellman S. Advances in radiotherapy and implications for the next century: a historical perspective. Cancer Res 2009, 69(2):383-392.
6. Clarke M.F., Dick J.E., Dirks P.B., Eaves C.J., Jamieson C.H., Jones D.L., et al. Cancer stem cells-perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res 2006, 66(19):9339-9344.
7. Reya T., Morrison S.J., Clarke M.F., Weissman I.L. Stem cells, cancer, and cancer stem cells. Nature 2001, 414(6859):105-111.
8. Dingli D., Michor F. Successful therapy must eradicate cancer stem cells. Stem Cells 2006, 24(12):2603-2610.
9. Baumann M., Krause M., Hill R. Exploring the role of cancer stem cells in radioresistance. Nat Rev Cancer 2008, 8(7):545-554.
10. Baumann M., Krause M., Thames H., Trott K., Zips D. Cancer stem cells and radiotherapy. Int J Radiat Biol 2009, 85(5):391-402.
11. Hewitt H.B., Blake E.R., Walder A.S. A critique of the evidence for active host defence against cancer, based on personal studies of 27 murine tumours of spontaneous origin. Br J Cancer 1976, 33(3):241-259.
12. Hill R.P., Milas L. The proportion of stem cells in murine tumors. Int J Radiat Oncol Biol Phys 1989, 16(2):513-518.
13. Kummermehr J., Trott K.R. Tumour stem cells 1997, 363-400. Academic Press Limited, London. C.S. Potten (Ed.).
14. Suit H.D., Rockwell S., Zietman A., Silobrcic V., Porter E.A., Ramsay J., et al. Quantitative transplantation assays of the rat rhabdomyosarcoma BA1112 isografts into the WAG/Rij Y rat and xenotransplantation into the athymic NCr (nu/nu) nude mouse. Eur J Cancer Clin Oncol 1989, 25(10):1463-1466.
15. Suit H.D., Sedlacek R.S., Zietman A. Quantitative transplantation assays of spontaneous tumors of the C3H mouse as allografts in athymic NCr/Sed-nu/nu nude mice and isografts in C3Hf/Sed mice. Cancer Res 1988, 48(16):4525-4528.
16. Taghian A., Budach W., Zietman A., Freeman J., Gioioso D., Ruka W., et al. Quantitative comparison between the transplantability of human and murine tumors into the subcutaneous tissue of NCr/Sed-nu/nu nude and severe combined immunodeficient mice. Cancer Res 1993, 53(20):5012-5017.
17. Taghian A., Budach W., Zietman A., Freeman J., Gioioso D., Suit H.D. Quantitative comparison between the transplantability of human and murine tumors into the brain of NCr/Sed-nu/nu nude and severe combined immunodeficient mice. Cancer Res 1993, 53(20):5018-5021.
18. Zietman A.L., Suit H.D., Ramsay J.R., Silobrcic V., Sedlacek R.S. Quantitative studies on the transplantability of murine and human tumors into the brain and subcutaneous tissues of NCr/Sed nude mice. Cancer Res 1988, 48(22):6510-6516.
19. Southam C.M., Brunschwig A. Quantitative studies of autotransplantation of human cancer. Cancer Cell 1961, 14:971-978.
20. Southam C.M., Brunschwig A., Dizon Q. Autologous and homologous transplantation of human cancer. Biological interactions in normal and neoplastic growth 1962, Churchill, London. H.J. Brennan, W.L. Simpson (Eds.).
21. Schatton T., Frank N.Y., Frank M.H. Identification and targeting of cancer stem cells. Bioessays 2009, 31(10):1038-1049.
22. Visvader J.E., Lindeman G.J. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 2008, 8(10):755-768.
23. Vermeulen L., Sprick M.R., Kemper K., Stassi G., Medema J.P. Cancer stem cells-old concepts, new insights. Cell Death Differ 2008, 15(6):947-958.
24. Zheng X., Shen G., Yang X., Liu W. Most C6 cells are cancer stem cells: evidence from clonal and population analyses. Cancer Res 2007, 67(8):3691-3697.
25. Shmelkov S.V., Butler J.M., Hooper A.T., Hormigo A., Kushner J., Milde T., et al. CD133 expression is not restricted to stem cells, and both CD133+ and CD133- metastatic colon cancer cells initiate tumors. J Clin Invest 2008, 118(6):2111-2120.
26. Quintana E., Shackleton M., Sabel M.S., Fullen D.R., Johnson T.M., Morrison S.J. Efficient tumour formation by single human melanoma cells. Nature 2008, 456(7222):593-598.
27. Wang J., Sakariassen P.O., Tsinkalovsky O., Immervoll H., Boe S.O., Svendsen A., et al. CD133 negative glioma cells form tumors in nude rats and give rise to CD133 positive cells. Int J Cancer 2008, 122(4):761-768.
28. Gilbert C.A., Ross A.H. Cancer stem cells: cell culture, markers, and targets for new therapies. J Cell Biochem 2009, 108(5):1031-1038.
29. Wang J., Guo L.P., Chen L.Z., Zeng Y.X., Lu S.H. Identification of cancer stem cell-like side population cells in human nasopharyngeal carcinoma cell line. Cancer Res 2007, 67(8):3716-3724.
30. Morita Y., Ema H., Yamazaki S., Nakauchi H. Non-side-population hematopoietic stem cells in mouse bone marrow. Blood 2006, 108(8):2850-2856.
31. Stingl J., Eirew P., Ricketson I., Shackleton M., Vaillant F., Choi D., et al. Purification and unique properties of mammary epithelial stem cells. Nature 2006, 439(7079):993-997.
32. Srivastava V.K., Nalbantoglu J. Flow cytometric characterization of the DAOY medulloblastoma cell line for the cancer stem-like phenotype. Cytometry A 2008, 73(10):940-948.
33. Alektiar K.M., Velasco J., Zelefsky M.J., Woodruff J.M., Lewis J.J., Brennan M.F. Adjuvant radiotherapy for margin-positive high-grade soft tissue sarcoma of the extremity. Int J Radiat Oncol Biol Phys 2000, 48(4):1051-1058.
34. Barrow B.J., Janjan N.A., Gutman H., Benjamin R.S., Allen P., Romsdahl M.M., et al. Role of radiotherapy in sarcoma of the breast--a retrospective review of the M.D. Anderson experience. Radiother Oncol 1999, 52(2):173-178.
35. Loree T.R., Strong E.W. Significance of positive margins in oral cavity squamous carcinoma. Am J Surg 1990, 160(4):410-414.
36. Swindle P., Eastham J.A., Ohori M., Kattan M.W., Wheeler T., Maru N., et al. Do margins matter? The prognostic significance of positive surgical margins in radical prostatectomy specimens. J Urol 2005, 174(3):903-907.
37. Wiegel T., Bottke D., Steiner U., Siegmann A., Golz R., Storkel S., et al. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol 2009, 27(18):2924-2930.
38. Fusi A., Collette S., Busse A., Suciu S., Rietz A., Santinami M., et al. Circulating melanoma cells and distant metastasis-free survival in stage III melanoma patients with or without adjuvant interferon treatment (EORTC 18991 side study). Eur J Cancer 2009, 45(18):3189-3197.
39. Riethdorf S., Wikman H., Pantel K. Review: Biological relevance of disseminated tumor cells in cancer patients. Int J Cancer 2008, 123(9):1991-2006.
40. Peters L.J., Withers H.R., Thames H.D., Fletcher G.H. Tumor radioresistance in clinical radiotherapy. Int J Radiat Oncol Biol Phys 1982, 8(1):101-108.
41. Munro T.R., Gilbert C.W. The relation between tumour lethal doses and the radiosensitivity of tumour cells. Br J Radiol 1961, 34:246-251.
42. Suit H., Shalek R., Wette R. Radiation response of C3H mouse mammary carcinoma evaluated in terms of cellular radiation sensitivity. Cellular Radiation Biology 1965, Williams and Wilkins, Baltimore, p. 514-530.
43. Baumann M., Dubois W., Suit H.D. Response of human squamous cell carcinoma xenografts of different sizes to irradiation: relationship of clonogenic cells, cellular radiation sensitivity in vivo, and tumor rescuing units. Radiat Res 1990, 123(3):325-330.
44. Suit H.D., Sedlacek R., Thames H.D. Rodent tumor models in experimental cancer therapy 1987, 138-148. Pergamon Press, New York. R.F. Kallman (Ed.).
45. Krause M., Zips D., Thames H.D., Kummermehr J., Baumann M. Preclinical evaluation of molecular-targeted anticancer agents for radiotherapy. Radiother Oncol 2006, 80(2):112-122.
46. Bentzen S.M. Dose-response relationships in radiotherapy 2009, Hodder Arnold, London. fourth ed.
47. Yaromina A., Krause M., Thames H., Rosner A., Krause M., Hessel F., et al. Pre-treatment number of clonogenic cells and their radiosensitivity are major determinants of local tumour control after fractionated irradiation. Radiother Oncol 2007, 83(3):304-310.
48. Suit H., Maeda M. Oxygen effect factor and tumor volume in the C3H mouse mammary carcinoma. A preliminary report. Am J Roentgenol Radium Ther Nucl Med 1966, 96(1):177-182.
49. Bentzen S.M., Thames H.D. Tumor volume and local control probability: clinical data and radiobiological interpretations. Int J Radiat Oncol Biol Phys 1996, 36(1):247-251.
50. Dubben H.H., Thames H.D., Beck-Bornholdt H.P. Tumor volume: a basic and specific response predictor in radiotherapy. Radiother Oncol 1998, 47(2):167-174.
51. Johnson C.R., Thames H.D., Huang D.T., Schmidt-Ullrich R.K. The tumor volume and clonogen number relationship: tumor control predictions based upon tumor volume estimates derived from computed tomography. Int J Radiat Oncol Biol Phys 1995, 33(2):281-287.
52. Withers H.R. The four R's of radiotherapy. Advances in radiation biology 1975, 241-247. Academic Press, NewYork. J.T. Lett, H. Adler (Eds.).
53. Pajonk F., Vlashi E., McBride W.H. Radiation Resistance of Cancer Stem Cells-the 4R's of radiobiology revisited. Stem Cells 2010, Feb 4, Epub ahead of print.
54. Baumann M., Liertz C., Baisch H., Wiegel T., Lorenzen J., Arps H. Impact of overall treatment time of fractionated irradiation on local control of human FaDu squamous cell carcinoma in nude mice. Radiother Oncol 1994, 32(2):137-143.
55. Petersen C., Zips D., Krause M., Volkel W., Thames H.D., Baumann M. Recovery from sublethal damage during fractionated irradiation of human FaDu SCC. Radiother Oncol 2005, 74(3):331-336.
56. Hessel F., Krause M., Helm A., Petersen C., Grenman R., Thames H.D., et al. Differentiation status of human squamous cell carcinoma xenografts does not appear to correlate with the repopulation capacity of clonogenic tumour cells during fractionated irradiation. Int J Radiat Biol 2004, 80(10):719-727.
57. Hessel F., Krause M., Petersen C., Horcsoki M., Klinger T., Zips D., et al. Repopulation of moderately well-differentiated and keratinizing GL human squamous cell carcinomas growing in nude mice. Int J Radiat Oncol Biol Phys 2004, 58(2):510-518.
58. Petersen C., Zips D., Krause M., Schone K., Eicheler W., Hoinkis C., et al. Repopulation of FaDu human squamous cell carcinoma during fractionated radiotherapy correlates with reoxygenation. Int J Radiat Oncol Biol Phys 2001, 51(2):483-493.
59. Petersen C., Baumann M., Dubben H.H., Arps H., Melenkeit A., Helfrich J. Linear-quadratic analysis of tumour response to fractionated radiotherapy: a study on human squamous cell carcinoma xenografts. Int J Radiat Biol 1998, 73(2):197-205.
60. Baumann M., Petersen C., Schulz P., Baisch H. Impact of overall treatment time on local control of slow growing human GL squamous cell carcinoma in nude mice treated by fractionated irradiation. Radiother Oncol 1999, 50(1):107-111.
61. Baumann M., Bentzen S.M., Ang K.K. Hyperfractionated radiotherapy in head and neck cancer: a second look at the clinical data. Radiother Oncol 1998, 46(2):127-130.
62. Petersen C., Eicheler W., Frommel A., Krause M., Balschukat S., Zips D., et al. Proliferation and micromilieu during fractionated irradiation of human FaDu squamous cell carcinoma in nude mice. Int J Radiat Biol 2003, 79(7):469-477.
63. Bao S., Wu Q., McLendon R.E., Hao Y., Shi Q., Hjelmeland A.B., et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006, 444(7120):756-760.
64. Bao S., Wu Q., Sathornsumetee S., Hao Y., Li Z., Hjelmeland A.B., et al. Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res 2006, 66(16):7843-7848.
65. Blazek E.R., Foutch J.L., Maki G. Daoy medulloblastoma cells that express CD133 are radioresistant relative to CD133- cells, and the CD133+ sector is enlarged by hypoxia. Int J Radiat Oncol Biol Phys 2007, 67(1):1-5.
66. Chang C.J., Hsu C.C., Yung M.C., Chen K.Y., Tzao C., Wu W.F., et al. Enhanced radiosensitivity and radiation-induced apoptosis in glioma CD133-positive cells by knockdown of SirT1 expression. Biochem Biophys Res Commun 2009, 380(2):236-242.
67. Chen M.S., Woodward W.A., Behbod F., Peddibhotla S., Alfaro M.P., Buchholz T.A., et al. Wnt/beta-catenin mediates radiation resistance of Sca1+ progenitors in an immortalized mammary gland cell line. J Cell Sci 2007, 120(Pt 3):468-477.
68. Chiou S.H., Kao C.L., Chen Y.W., Chien C.S., Hung S.C., Lo J.F., et al. Identification of CD133-positive radioresistant cells in atypical teratoid/rhabdoid tumor. PLoS One 2008, 3(5):e2090.
69. Kao C.L., Huang P.I., Tsai P.H., Tsai M.L., Lo J.F., Lee Y.Y., et al. Resveratrol-induced apoptosis and increased radiosensitivity in CD133-positive cells derived from atypical teratoid/rhabdoid tumor. Int J Radiat Oncol Biol Phys 2009, 74(1):219-228.
70. McCord A.M., Jamal M., Shankavaram U.T., Lang F.F., Camphausen K., Tofilon P.J. Physiologic oxygen concentration enhances the stem-like properties of CD133+ human glioblastoma cells in vitro. Mol Cancer Res 2009, 7(4):489-497.
71. McCord A.M., Jamal M., Williams E.S., Camphausen K., Tofilon P.J. CD133+ glioblastoma stem-like cells are radiosensitive with a defective DNA damage response compared with established cell lines. Clin Cancer Res 2009, 15(16):5145-5153.
72. Phillips T.M., McBride W.H., Pajonk F. The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation. J Natl Cancer Inst 2006, 98(24):1777-1785.
73. Platet N., Liu S.Y., Atifi M.E., Oliver L., Vallette F.M., Berger F., et al. Influence of oxygen tension on CD133 phenotype in human glioma cell cultures. Cancer Lett 2007, 258(2):286-290.
74. Woodward W.A., Chen M.S., Behbod F., Alfaro M.P., Buchholz T.A., Rosen J.M. WNT/beta-catenin mediates radiation resistance of mouse mammary progenitor cells. Proc Natl Acad Sci USA 2007, 104(2):618-623.
75. Takaishi S., Okumura T., Tu S., Wang S.S., Shibata W., Vigneshwaran R., et al. Identification of gastric cancer stem cells using the cell surface marker CD44. Stem Cells 2009, 27(5):1006-1020.
76. Dean M., Fojo T., Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer 2005, 5(4):275-284.
77. Kang M.K., Kang S.K. Tumorigenesis of chemotherapeutic drug-resistant cancer stem-like cells in brain glioma. Stem Cells Dev 2007, 16(5):837-847.
78. Liu G., Yuan X., Zeng Z., Tunici P., Ng H., Abdulkadir I.R., et al. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer 2006, 5:67.
79. Ghods A.J., Irvin D., Liu G., Yuan X., Abdulkadir I.R., Tunici P., et al. Spheres isolated from 9L gliosarcoma rat cell line possess chemoresistant and aggressive cancer stem-like cells. Stem Cells 2007, 25(7):1645-1653.
80. Eramo A., Ricci-Vitiani L., Zeuner A., Pallini R., Lotti F., Sette G., et al. Chemotherapy resistance of glioblastoma stem cells. Cell Death Differ 2006, 13(7):1238-1241.
81. Ma S., Lee T.K., Zheng B.J., Chan K.W., Guan X.Y. CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway. Oncogene 2008, 27(12):1749-1758.
82. Marangoni E., Lecomte N., Durand L., de Pinieux G., Decaudin D., Chomienne C., et al. CD44 targeting reduces tumour growth and prevents post-chemotherapy relapse of human breast cancers xenografts. Br J Cancer 2009, 100(6):918-922.
83. Hong S.P., Wen J., Bang S., Park S., Song S.Y. CD44-positive cells are responsible for gemcitabine resistance in pancreatic cancer cells. Int J Cancer 2009, 125(10):2323-2331.
84. Al-Assar O., Muschel R.J., Mantoni T.S., McKenna W.G., Brunner T.B. Radiation response of cancer stem-like cells from established human cell lines after sorting for surface markers. Int J Radiat Oncol Biol Phys 2009, 75(4):1216-1225.
85. Dittfeld C., Dietrich A., Peickert S., Hering S., Baumann M., Grade M., et al. CD133 expression is not selective for tumor-initiating or radioresistant cell populations in the CRC cell lines HCT-116. Radiother Oncol 2009, 92(3):353-361.
86. van Staveren W.C., Solis D.Y., Hebrant A., Detours V., Dumont J.E., Maenhaut C. Human cancer cell lines: experimental models for cancer cells in situ? For cancer stem cells?'. Biochim Biophys Acta 2009, 1795(2):92-103.
87. Lee J., Kotliarova S., Kotliarov Y., Li A., Su Q., Donin N.M., et al. Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell 2006, 9(5):391-403.
88. Tannock I.F., Lee C. Evidence against apoptosis as a major mechanism for reproductive cell death following treatment of cell lines with anti-cancer drugs. Br J Cancer 2001, 84(1):100-105.
89. Brown J.M., Attardi L.D. The role of apoptosis in cancer development and treatment response. Nat Rev Cancer 2005, 5(3):231-237.
90. Murat A., Migliavacca E., Gorlia T., Lambiv W.L., Shay T., Hamou M.F., et al. Stem cell-related " self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. J Clin Oncol 2008, 26(18):3015-3024.
91. Pallini R., Ricci-Vitiani L., Banna G.L., Signore M., Lombardi D., Todaro M., et al. Cancer stem cell analysis and clinical outcome in patients with glioblastoma multiforme. Clin Cancer Res 2008, 14(24):8205-8212.
92. Zeppernick F., Ahmadi R., Campos B., Dictus C., Helmke B.M., Becker N., et al. Stem cell marker CD133 affects clinical outcome in glioma patients. Clin Cancer Res 2008, 14(1):123-129.
93. Wang Q., Chen Z.G., Du C.Z., Wang H.W., Yan L., Gu J. Cancer stem cell marker CD133+ tumour cells and clinical outcome in rectal cancer. Histopathology 2009, 55(3):284-293.
94. Begg A.C. Predicting response to radiotherapy: evolutions and revolutions. Int J Radiat Biol 2009, 85(10):825-836.
95. De Jong M.C., Pramana J., Lacko M., Peutz-Kootstra C.J., de Jong J.M., Takes R.P., et al. Prediction of local recurrence after radiotherapy in head and neck cancer by expression profiling. Radiother Oncol 2009, 90(Suppl. 3):S62.
96. Joiner M., Van der Kogel A. Basic clinical radiobiology 2009, Hodder Arnold, London.
97. Baumann M., DuBois W., Pu A., Freeman J., Suit H.D. Response of xenografts of human malignant gliomas and squamous cell carcinomas to fractionated irradiation. Int J Radiat Oncol Biol Phys 1992, 23(4):803-809.
98. Krause M., Ostermann G., Petersen C., Yaromina A., Hessel F., Harstrick A., et al. Decreased repopulation as well as increased reoxygenation contribute to the improvement in local control after targeting of the EGFR by C225 during fractionated irradiation. Radiother Oncol 2005, 76(2):162-167.
99. Krause M., Schutze C., Petersen C., Pimentel N., Hessel F., Harstrick A., et al. Different classes of EGFR inhibitors may have different potential to improve local tumour control after fractionated irradiation: a study on C225 in FaDu hSCC. Radiother Oncol 2005, 74(2):109-115.
100. Kozin S.V., Boucher Y., Hicklin D.J., Bohlen P., Jain R.K., Suit H.D. Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-induced long-term control of human tumor xenografts. Cancer Res 2001, 61(1):39-44.
101. Nasu S., Ang K.K., Fan Z., Milas L. C225 antiepidermal growth factor receptor antibody enhances tumor radiocurability. Int J Radiat Oncol Biol Phys 2001, 51(2):474-477.
102. Krause M., Wohlfarth J., Georgi B., Pimentel N., Dorner D., Zips D., et al. Low-dose hyperradiosensitivity of human glioblastoma cell lines in vitro does not translate into improved outcome of ultrafractionated radiotherapy in vivo. Int J Radiat Biol 2005, 81(10):751-758.
103. Krause M., Hessel F., Zips D., Hilberg F., Baumann M. Adjuvant inhibition of the epidermal growth factor receptor after fractionated irradiation of FaDu human squamous cell carcinoma. Radiother Oncol 2004, 72(1):95-101.
104. Krause M., Prager J., Zhou X., Yaromina A., Dorfler A., Eicheler W., et al. EGFR-TK inhibition before radiotherapy reduces tumour volume but does not improve local control: differential response of cancer stem cells and nontumourigenic cells?. Radiother Oncol 2007, 83(3):316-325.
105. Baumann M., Krause M., Zips D., Eicheler W., Dorfler A., Ahrens J., et al. Selective inhibition of the epidermal growth factor receptor tyrosine kinase by BIBX1382BS and the improvement of growth delay, but not local control, after fractionated irradiation in human FaDu squamous cell carcinoma in the nude mouse. Int J Radiat Biol 2003, 79(7):547-559.
106. Zips D., Hessel F., Krause M., Schiefer Y., Hoinkis C., Thames H.D., et al. Impact of adjuvant inhibition of vascular endothelial growth factor receptor tyrosine kinases on tumor growth delay and local tumor control after fractionated irradiation in human squamous cell carcinomas in nude mice. Int J Radiat Oncol Biol Phys 2005, 61(3):908-914.
107. Zips D., Krause M., Hessel F., Westphal J., Bruchner K., Eicheler W., et al. Experimental study on different combination schedules of VEGF-receptor inhibitor PTK787/ZK222584 and fractionated irradiation. Anticancer Res 2003, 23(5A):3869-3876.
108. Zips D., Le K., Yaromina A., Dorfler A., Eicheler W., Zhou X., et al. Triple angiokinase inhibition, tumour hypoxia and radiation response of FaDu human squamous cell carcinomas. Radiother Oncol 2009, 92(3):405-410.
109. Weppler S.A., Krause M., Zyromska A., Lambin P., Baumann M., Wouters B.G. Response of U87 glioma xenografts treated with concurrent rapamycin and fractionated radiotherapy: possible role for thrombosis. Radiother Oncol 2007, 82(1):96-104.
110. Krause M., Gurtner K., Deuse Y., Eicheler W., Baumann M. Local tumour control after simultaneous fractionated irradiation and EGFR-blockade by monoclonal antibodies (Cetuximab) versus tyrosine kinase inhibitors (Erlotinib) in different head and neck squamous cell carcinoma (HNSCC) models. Eur J Cancer Suppl 2009, 7(2):153.
111. Yaromina A., Holscher T., Eicheler W., Rosner A., Krause M., Hessel F., et al. Does heterogeneity of pimonidazole labelling correspond to the heterogeneity of radiation-response of FaDu human squamous cell carcinoma?. Radiother Oncol 2005, 76(2):206-212.
112. Walenta S., Mueller-Klieser W.F. Lactate: mirror and motor of tumor malignancy. Semin Radiat Oncol 2004, 14(3):267-274.
113. Hill R.P., Marie-Egyptienne D.T., Hedley D.W. Cancer stem cells, hypoxia and metastasis. Semin Radiat Oncol 2009, 19(2):106-111.
114. Vaupel P., Mayer A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev 2007, 26(2):225-239.
115. Quennet V., Yaromina A., Zips D., Rosner A., Walenta S., Baumann M., et al. Tumor lactate content predicts for response to fractionated irradiation of human squamous cell carcinomas in nude mice. Radiother Oncol 2006, 81(2):130-135.
116. Sattler U.G., Meyer S.S., Quennet V., Hoerner C., Knoerzer H., Fabian C., et al. Glycolytic metabolism and tumour response to fractionated irradiation. Radiother Oncol 2010, 94(1):102-109.
117. Sonveaux P., Vegran F., Schroeder T., Wergin M.C., Verrax J., Rabbani Z.N., et al. Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. J Clin Invest 2008, 118(12):3930-3942.
118. Walenta S., Wetterling M., Lehrke M., Schwickert G., Sundfor K., Rofstad E.K., et al. High lactate levels predict likelihood of metastases, tumor recurrence, and restricted patient survival in human cervical cancers. Cancer Res 2000, 60(4):916-921.
119. Gray L.H., Conger A.D., Ebert M., Hornsey S., Scott O.C. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol 1953, 26(312):638-648.
120. Wright E.A., Howard-Flanders P. The influence of oxygen on the radiosensitivity of mammalian tissues. Acta radiol 1957, 48(1):26-32.
121. Yaromina A., Zips D., Thames H.D., Eicheler W., Krause M., Rosner A., et al. Pimonidazole labelling and response to fractionated irradiation of five human squamous cell carcinoma (hSCC) lines in nude mice: the need for a multivariate approach in biomarker studies. Radiother Oncol 2006, 81(2):122-129.
122. Schreiber A., Krause M., Zips D., Dorfler A., Richter K., Vettermann S., et al. Effect of the hypoxic cell sensitizer isometronidazole on local control of two human squamous cell carcinomas after fractionated irradiation. Strahlenther Onkol 2004, 180(6):375-382.
123. Kaanders J.H., Wijffels K.I., Marres H.A., Ljungkvist A.S., Pop L.A., van den Hoogen F.J., et al. Pimonidazole binding and tumor vascularity predict for treatment outcome in head and neck cancer. Cancer Res 2002, 62(23):7066-7074.
124. Overgaard J., Eriksen J.G., Nordsmark M., Alsner J., Horsman M.R. Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: results from the DAHANCA 5 randomised double-blind placebo-controlled trial. Lancet Oncol 2005, 6(10):757-764.
125. Nordsmark M., Bentzen S.M., Rudat V., Brizel D., Lartigau E., Stadler P., et al. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother Oncol 2005, 77(1):18-24.
126. Cordes N., Hehlgans S., Eke I. Adhesion, invasion, integrins, and beyond. The impact of tumor biology on cancer treatment and multidisciplinary strategies 2009, 93-115. Springer, Berlin. M. Molls, P. Vaupel, C. Nieder, M.S. Anscher (Eds.).
127. Sandfort V., Koch U., Cordes N. Cell adhesion-mediated radioresistance revisited. Int J Radiat Biol 2007, 83(11-12):727-732.
128. Sung S.Y., Hsieh C.L., Wu D., Chung L.W., Johnstone P.A. Tumor microenvironment promotes cancer progression, metastasis, and therapeutic resistance. Curr Probl Cancer 2007, 31(2):36-100.
129. Kunz-Schughart L.A., Knuechel R. Tumor-associated fibroblasts (part II): functional impact on tumor tissue. Histol Histopathol 2002, 17(2):623-637.
130. Kunz-Schughart L.A., Knuechel R. Tumor-associated fibroblasts (part I): active stromal participants in tumor development and progression?. Histol Histopathol 2002, 17(2):599-621.
131. Meads M.B., Gatenby R.A., Dalton W.S. Environment-mediated drug resistance: a major contributor to minimal residual disease. Nat Rev Cancer 2009, 9(9):665-674.
132. Ghotra V.P., Puigvert J.C., Danen E.H. The cancer stem cell microenvironment and anti-cancer therapy. Int J Radiat Biol 2009, 85(11):955-962.
133. Iwasaki H., Suda T. Cancer stem cells and their niche. Cancer Sci 2009, 100(7):1166-1172.
134. Jin L., Hope K.J., Zhai Q., Smadja-Joffe F., Dick J.E. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med 2006, 12(10):1167-1174.
135. Krause D.S., Lazarides K., von Andrian U.H., Van Etten R.A. Requirement for CD44 in homing and engraftment of BCR-ABL-expressing leukemic stem cells. Nat Med 2006, 12(10):1175-1180.
136. Calabrese C., Poppleton H., Kocak M., Hogg T.L., Fuller C., Hamner B., et al. A perivascular niche for brain tumor stem cells. Cancer Cell 2007, 11(1):69-82.
137. Ferrara N., Kerbel R.S. Angiogenesis as a therapeutic target. Nature 2005, 438(7070):967-974.
138. Zhou B.B., Zhang H., Damelin M., Geles K.G., Grindley J.C., Dirks P.B. Tumour-initiating cells: challenges and opportunities for anticancer drug discovery. Nat Rev Drug Discov 2009, 8(10):806-823.
139. Eyler C.E., Rich J.N. Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis. J Clin Oncol 2008, 26(17):2839-2845.
140. Frank N.Y., Schatton T., Frank M.H. The therapeutic promise of the cancer stem cell concept. J Clin Invest 2009, 120(1):41-50.
141. Yang Z.J., Wechsler-Reya R.J. Hit 'em where they live: targeting the cancer stem cell niche. Cancer Cell 2007, 11(1):3-5.
142. Rich J.N. Cancer stem cells in radiation resistance. Cancer Res 2007, 67(19):8980-8984.
143. Zips D., Baumann M. Anti-VEGF strategies in combination with radiotherapy. Modification of radiation response-cytokines, growth factors and other biological targets 2003, Springer, Berlin, p. 179-88.
144. Ebos J.M., Lee C.R., Cruz-Munoz W., Bjarnason G.A., Christensen J.G., Kerbel R.S. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009, 15(3):232-239.
145. Paez-Ribes M., Allen E., Hudock J., Takeda T., Okuyama H., Vinals F., et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009, 15(3):220-231.
146. Hu C.J., Wang L.Y., Chodosh L.A., Keith B., Simon M.C. Differential roles of hypoxia-inducible factor 1alpha (HIF-1alpha) and HIF-2alpha in hypoxic gene regulation. Mol Cell Biol 2003, 23(24):9361-9374.
147. Covello K.L., Kehler J., Yu H., Gordan J.D., Arsham A.M., Hu C.J., et al. HIF-2alpha regulates Oct-4: effects of hypoxia on stem cell function, embryonic development, and tumor growth. Genes Dev 2006, 20(5):557-570.
148. Gordan J.D., Bertout J.A., Hu C.J., Diehl J.A., Simon M.C. HIF-2alpha promotes hypoxic cell proliferation by enhancing c-myc transcriptional activity. Cancer Cell 2007, 11(4):335-347.
149. Gordan J.D., Simon M.C. Hypoxia-inducible factors: central regulators of the tumor phenotype. Curr Opin Genet Dev 2007, 17(1):71-77.
150. Gustafsson M.V., Zheng X., Pereira T., Gradin K., Jin S., Lundkvist J., et al. Hypoxia requires notch signaling to maintain the undifferentiated cell state. Dev Cell 2005, 9(5):617-628.
151. Semenza G.L. Evaluation of HIF-1 inhibitors as anticancer agents. Drug Discov Today 2007, 12(19-20):853-859.
152. Hockel M., Schlenger K., Aral B., Mitze M., Schaffer U., Vaupel P. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 1996, 56(19):4509-4515.
153. Hockel M., Knoop C., Schlenger K., Vorndran B., Baussmann E., Mitze M., et al. Intratumoral pO2 predicts survival in advanced cancer of the uterine cervix. Radiother Oncol 1993, 26(1):45-50.
154. Fyles A., Milosevic M., Hedley D., Pintilie M., Levin W., Manchul L., et al. Tumor hypoxia has independent predictor impact only in patients with node-negative cervix cancer. J Clin Oncol 2002, 20(3):680-687.
155. 2-measurements as predictive assay in the treatment of carcinoma of the uterine cervix. Radiother Oncol 1999, 53(2):99-104.
156. Lyng H., Sundfor K., Trope C., Rofstad E.K. Disease control of uterine cervical cancer: relationships to tumor oxygen tension, vascular density, cell density, and frequency of mitosis and apoptosis measured before treatment and during radiotherapy. Clin Cancer Res 2000, 6(3):1104-1112.
157. Overgaard J. Hypoxic radiosensitization: adored and ignored. J Clin Oncol 2007, 25(26):4066-4074.
158. Overgaard J., Overgaard M., Nielsen O.S., Pedersen A.K., Timothy A.R. A comparative investigation of nimorazole and misonidazole as hypoxic radiosensitizers in a C3H mammary carcinoma in vivo. Br J Cancer 1982, 46(6):904-911.
159. Overgaard J., Hansen H.S., Overgaard M., Bastholt L., Berthelsen A., Specht L., et al. A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85. Radiother Oncol 1998, 46(2):135-146.
160. Kaanders J.H., Pop L.A., Marres H.A., Bruaset I., van den Hoogen F.J., Merkx M.A., et al. ARCON: experience in 215 patients with advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 2002, 52(3):769-778.
161. Bentzen S.M. Theragnostic imaging for radiation oncology: dose-painting by numbers. Lancet Oncol 2005, 6(2):112-117.
162. Ling C.C., Humm J., Larson S., Amols H., Fuks Z., Leibel S., et al. Towards multidimensional radiotherapy (MD-CRT): biological imaging and biological conformality. Int J Radiat Oncol Biol Phys 2000, 47(3):551-560.
163. Denekamp J. Tumour stem cells: facts, interpretation and consequences. Radiother Oncol 1994, 30(1):6-10.
164. Hendry J.H., West C.M., Moore J.V., Potten C.S. Tumour stem cells: the relevance of predictive assays for tumour control after radiotherapy. Radiother Oncol 1994, 30(1):11-16.
165. Trott K.R. Tumour stem cells: the biological concept and its application in cancer treatment. Radiother Oncol 1994, 30(1):1-5.
166. Woodward W.A., Bristow R.G., Clarke M.F., Coppes R.P., Cristofanilli M., Duda D.G., et al. Radiation Therapy Oncology Group translational research program stem cell symposium: incorporating stem cell hypotheses into clinical trials. Int J Radiat Oncol Biol Phys 2009, 74(5):1580-1591.
167. Baumann M., Holscher T., Begg A.C. Towards genetic prediction of radiation responses: ESTRO's GENEPI project. Radiother Oncol 2003, 69(2):121-125.
168. Murohashi M., Hinohara K., Kuroda M., Isagawa T., Tsuji S., Kobayashi S., et al. Gene set enrichment analysis provides insight into novel signalling pathways in breast cancer stem cells. Br J Cancer 2009.
169. Liu R., Wang X., Chen G.Y., Dalerba P., Gurney A., Hoey T., et al. The prognostic role of a gene signature from tumorigenic breast-cancer cells. N Engl J Med 2007, 356(3):217-226.